Tong X, Bogen S, Chase R, Girijavallabhan V, Guo Z, Njoroge FG, Prongay A, Saksena A, Skelton A, Xia. Characterization of resistance mutations against HCV ketoamide protease inhibitors.. Antiviral Res.. 2008. 77(3). 177-185. Find at Google Scholar.
Liverton NJ, Carroll SS, Dimuzio J, Fandozzi C, Graham DJ, Hazuda D, Holloway MK, Ludmerer SW, McCau. MK-7009, a potent and selective inhibitor of hepatitis C virus NS3/4A protease. . Antimicrob Agents Chemother. 2010. 54(1). 305-311. Find at Google Scholar.
Vermehren J, Susser S, Lange CM, Forestier N, Karey U, Hughes E, Ralston R, Tong X, Zeuzem S, Sarraz. Mutations selected in the hepatitis C virus NS3 protease domain during sequential treatment with boc. J Viral Hepat. . 2012. 19(2). 120-127. Find at Google Scholar.
Kwong AD, Najera I, Bechtel J, Bowden S, Fitzgibbon J, Harrington P, Kempf D, Kieffer TL, Koletzki D. Sequence and phenotypic analysis for resistance monitoring in hepatitis C virus drug development: re. Gastroenterology. 2011. 140(3). 755-760. Find at Google Scholar.